All Releases
 |
Intellipharmaceutics Announces Webcast of Presentation at the 12th Annual Needham Healthcare Conference
Apr 24, 2013
|
14.4 KB |
|
| |
TORONTO, April 24, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief F...
|
|
Intellipharmaceutics Announces First Quarter 2013 Results
Apr 3, 2013
|
26.9 KB |
|
| |
TORONTO, April 3, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended Februar...
|
|
Intellipharmaceutics Closes US$3.1 Million Registered Direct Offering of Units
Mar 25, 2013
|
16.2 KB |
|
| |
TORONTO, March 25, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has closed its previously announced registered dir...
|
|
Intellipharmaceutics to Raise US$3.1 Million
Mar 19, 2013
|
16.1 KB |
|
| |
TORONTO, March 19, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it is raising approximately US$3.1 million in a regis...
|
|
Intellipharmaceutics Announces Update on Its Generic Versions of Keppra XR(R) and Pristiq(R)
Mar 13, 2013
|
14.9 KB |
|
| |
TORONTO, March 13, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an update on its generic versions of the marketed drugs Ke...
|
|
Intellipharmaceutics Announces 2012 Year End Results
Jan 31, 2013
|
30.1 KB |
|
| |
TORONTO, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 20...
|
|
Intellipharmaceutics Closes US$1.5 Million Convertible Debenture Financing
Jan 10, 2013
|
15.3 KB |
|
| |
TORONTO, Jan. 10, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has closed its previously-announced private placeme...
|
|
Intellipharmaceutics Announces Proposed Convertible Debenture Financing
Jan 7, 2013
|
15.6 KB |
|
| |
TORONTO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, is pleased to announce that it intends to complete a private placement finan...
|
|
Intellipharmaceutics Announces Results of Initial Phase I Clinical Trial of Controlled-Release Pregabalin and Product Updates
Nov 27, 2012
|
16.5 KB |
|
| |
TORONTO, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced successful results of an initial Phase I clinical trial of ...
|
|
Intellipharmaceutics to Present at the 24th Annual Piper Jaffray Healthcare Conference
Nov 21, 2012
|
15.0 KB |
|
| |
TORONTO, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Fi...
|
|
Intellipharmaceutics Announces Third Quarter 2012 Results
Oct 2, 2012
|
29.9 KB |
|
| |
TORONTO, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended...
|
|
Intellipharmaceutics Achieves a 2012 Goal by Filing Two ANDAs -- Generic Forms of Keppra XR(R) and Pristiq(R)
Sep 5, 2012
|
15.0 KB |
|
| |
TORONTO, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the achievement of another of its previously announced deve...
|
|
Intellipharmaceutics Settles Patent Litigation With AstraZeneca Concerning Generic Seroquel XR(R)
Jul 31, 2012
|
14.9 KB |
|
| |
TORONTO, July 31, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it had reached an agreement with AstraZeneca to settle...
|
|
Intellipharmaceutics International Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
Jul 10, 2012
|
16.6 KB |
|
| |
NEW YORK, July 10, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc.(Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, B.Sc., MBA, CA, Vice President Fina...
|
|
Intellipharmaceutics Announces Second Quarter 2012 Results
Jul 3, 2012
|
30.0 KB |
|
| |
TORONTO, July 3, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:...
|
|
Intellipharmaceutics Meets a 2012 Goal for Abuse-Deterrent Oxycodone
May 1, 2012
|
15.2 KB |
|
| |
TORONTO, May 1, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on its research and development activities and achie...
|
|
Intellipharmaceutics Announces First Quarter 2012 Results
Apr 12, 2012
|
27.3 KB |
|
| |
TORONTO, April 12, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc.(Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of n...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the 11th Annual Needham Healthcare Conference
Mar 27, 2012
|
13.8 KB |
|
| |
TORONTO, March 27, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief F...
|
|
Intellipharmaceutics Closes US$5,000,000 Registered Direct Offering of Common Shares
Mar 15, 2012
|
15.2 KB |
|
| |
TORONTO, March 15, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI)(TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has closed its previously announced registered dire...
|
|
Intellipharmaceutics to Raise US$5 Million
Mar 9, 2012
|
15.2 KB |
|
| |
TORONTO, March 9, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it is raising approximately US$5 million in a register...
|
|
|
